Specialties – Page 33

Machine Learning Accurately Predicts Distant Recurrence and Ribociclib Treatment Benefit in HR+/HER2- Early Breast Cancer

By MedXY 01/13/2026

Researchers have developed a machine learning model using real-world and clinical trial data to predict distant recurrence risk and ribociclib's therapeutic effect in HR+/HER2- early breast cancer, offering a potential tool for personalized adjuvant treatment decisions.

Clinical Updates Hematology-Oncology news

Clinical Evolution of Axicabtagene Ciloleucel: From Salvage Therapy to Second-Line Standard of Care

By MedXY 01/13/2026

This review synthesizes clinical trial evidence for Axicabtagene Ciloleucel, tracing its development from refractory B-cell lymphoma to its current role as a second-line standard and its expansion into indolent and mantle cell lymphomas.

$Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL$

news Oncology

Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL

By MedXY 01/13/2026

The ZUMA-6 trial investigated combining axicabtagene ciloleucel with atezolizumab for refractory DLBCL. While the combination was safe with a 54% complete response rate, efficacy and CAR T-cell expansion were comparable to monotherapy, highlighting the complexity of overcoming resistance in the tumor microenvironment.

news Oncology

Dual Inhibition of VEGF and EGFR: A New Precision Paradigm for Krebs Cycle-Mutated Solid Tumors

By MedXY 01/13/2026

The Phase II BRISK trial demonstrates that the combination of bevacizumab and erlotinib provides significant clinical activity in patients with solid tumors harboring Krebs cycle gene mutations, particularly in FH-deficient renal cell carcinoma and biliary tract cancers.

Gastroenterology news Oncology

HER2-Positivity in Advanced Biliary Tract Cancer: A Dual Role as a Negative Prognostic Factor and a Potent Therapeutic Vulnerability

By MedXY 01/13/2026

A multi-institutional analysis reveals that HER2-positivity in advanced biliary tract cancer signals a poorer prognosis but offers a significant survival benefit when targeted with anti-HER2 therapies, advocating for routine screening and standardized diagnostic criteria.

news Oncology Otorhinolaryngology

Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes

By MedXY 01/13/2026

A Phase II clinical trial demonstrates that combining tislelizumab with neoadjuvant chemotherapy significantly improves pathological response rates and organ preservation in patients with locally advanced head and neck squamous cell carcinoma.

news Oncology

T-DXd Combinations Redefine Therapeutic Boundaries in HER2-Low Metastatic Breast Cancer: Key Findings from DESTINY-Breast08

By MedXY 01/13/2026

The DESTINY-Breast08 phase 1b study demonstrates that trastuzumab deruxtecan (T-DXd) combined with chemotherapy, AKT inhibitors, or endocrine therapy is manageable and clinically active in HER2-low metastatic breast cancer, offering new pathways for treatment intensification.

$Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights$

news Oncology

Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights

By MedXY 01/13/2026

This Phase 3 trial demonstrates that pegylated liposomal doxorubicin significantly extends progression-free survival and improves response rates in patients with advanced desmoid tumors, offering a potent systemic option for refractory disease.

news Oncology

Beyond Breast Cancer: ESR1 Mutations Identified as Prevalent Primary Drivers in NSMP Low-Grade Endometrial Cancer

By MedXY 01/13/2026

Results from the UTOLA trial reveal that ESR1 mutations, a hallmark of AI resistance in breast cancer, are present in 22% of metastatic NSMP low-grade endometrial cancer patients before endocrine therapy, suggesting a need for molecular stratification in clinical practice.

news Oncology

SARC031 Trial: Why Combined MEK and mTOR Inhibition Failed to Translate from Mice to Men in MPNST

By MedXY 01/13/2026

The SARC031 Phase 2 trial evaluated selumetinib and sirolimus for advanced MPNST. Despite strong preclinical rationale, the combination showed minimal clinical benefit, though correlative studies on cfDNA and PET imaging offer vital insights for future biomarker-driven sarcoma research.

news Oncology

Atezolizumab Demonstrates Moderate Efficacy in TMB-High Solid Tumors: Insights from the TAPISTRY Phase II Trial

By MedXY 01/13/2026

The Phase II TAPISTRY trial evaluates atezolizumab in patients with high tumor mutational burden (TMB ≥13 or ≥16 mut/Mb), showing an objective response rate of approximately 20-22% across various solid tumors with a manageable safety profile.

news Oncology

Potent Immune Activation Fails to Translate into High Response Rates: Lessons from the Cergutuzumab Amunaleukin and Atezolizumab Phase Ib Trial

By MedXY 01/13/2026

A Phase Ib study of the IL-2 variant immunocytokine cergutuzumab amunaleukin plus atezolizumab demonstrates manageable safety and robust peripheral immune activation but modest clinical activity in CEA-positive advanced solid tumors.

Gastroenterology news Oncology

Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial

By MedXY 01/13/2026

A Phase II trial investigating the combination of cabozantinib and nivolumab in advanced extrapancreatic neuroendocrine tumors (epNETs) failed to meet its primary objective response rate endpoint, despite high rates of stable disease, highlighting the challenges of immunotherapy in these tumors.

news Oncology Urology

Breakthroughs in Prostate Cancer: Insights from the MetaCURE Multi-Modal Trial

By MedXY 01/13/2026

The MetaCURE trial demonstrates that combining surgery, radiation, and advanced hormonal therapies can achieve deep responses in high-risk prostate cancer, paving the way for faster drug development through intermediate clinical endpoints.

news Oncology Urology

Integrating Automated Radiomics with Serum Biomarkers Redefines Risk Stratification in Metastatic Castration-Resistant Prostate Cancer

By MedXY 01/13/2026

This article explores how novel automated imaging tools, combined with clinical biomarkers, enhance risk stratification in mCRPC, while also reviewing the pivotal OS data from abiraterone and enzalutamide trials that inform contemporary treatment standards.

Gastroenterology news Oncology

THAG Regimen Shows High Efficacy as Conversion Therapy for Pancreatic Cancer: New Phase II Trial Results

By MedXY 01/13/2026

A Phase II trial demonstrates that the THAG regimen—combining immunotherapy, radiotherapy, and chemotherapy—significantly improves R0 resection rates and survival in patients with BRPC and LAPC, supported by IL-6 and ctDNA biomarker insights.

news Oncology

HER2DX Genomic Testing Outperforms Traditional Histopathology in Predicting Neoadjuvant Therapy Response for HER2-Positive Breast Cancer

By MedXY 01/13/2026

This comprehensive analysis validates the HER2DX genomic assay as a robust tool that reflects tumor biology and independently predicts pathologic complete response, offering clinicians a precise instrument for personalizing treatment in early-stage HER2-positive breast cancer.

news Oncology

Targeting the PI3K/AKT Pathway: Ipatasertib Shows Promise as Maintenance Therapy for PIK3CA-Mutated, HER2-Positive Metastatic Breast Cancer

By MedXY 01/13/2026

The Phase 1b SOLTI-1507 IPATHER trial demonstrates that adding the AKT inhibitor ipatasertib to trastuzumab and pertuzumab is a safe and clinically active maintenance strategy for patients with PIK3CA-mutated HER2-positive metastatic breast cancer, potentially overcoming therapeutic resistance.

Gastroenterology news Oncology

Zanidatamab-Based Triplet Therapy Redefines Survival Expectations in HER2-Positive Gastric Cancer: Insights from a Phase 1b/2 Study

By MedXY 01/12/2026

A phase 1b/2 trial reveals that combining the bispecific antibody zanidatamab with tislelizumab and chemotherapy yields a 75.8% response rate and an impressive median overall survival of 32.4 months in first-line HER2-positive gastric and gastroesophageal junction cancer.

news Oncology

Synergistic Potential and Hematologic Hurdles: Sapacitabine and Olaparib in BRCA1/2-Mutated Metastatic Breast Cancer

By MedXY 01/12/2026

A Phase Ib study of sapacitabine and olaparib in gBRCA-mutated metastatic breast cancer showed a 50% objective response rate and 9.7-month median PFS. While significant hematological toxicities limited dose escalation, the combination demonstrated durable clinical benefit and provided key insights into resistance mechanisms.